Leishmaniasis: pathogenesis, host immunity, and the evolving landscape of immunotherapy and immunochemotherapy
Godspower N. Okeke, Ugochukwu K. Oduwe, Giorgi Kenkebashvili, Shefa Tabassum, Alexandre F. Marques · 2026
Read Leishmaniasis: pathogenesis, host immunity, and the evolving landscape of immunotherapy and immunochemotherapy by Godspower N. Okeke, Ugochukwu K. Oduwe, Giorgi Kenkebashvili, Shefa Tabassum, Alexandre F. Marques (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13342241.txt.
Description
Godspower N. Okeke and co-authors review leishmaniasis in 2026, a set of neglected tropical diseases spread by sandfly bites. The review covers how the parasites cause skin, mucosal, and visceral illness, how the host immune response decides the course, and how immune-based treatments are changing.
Protective immunity rests on Th1 responses, while Th2 skewing and IL-10 dominance let the disease advance. Standard drugs face resistance, kidney harm, relapse, and safety limits, and no licensed human vaccine exists. The authors weigh cytokine therapy, immune triggers, therapeutic vaccines, and mucosal delivery, arguing that pairing immune treatment with drugs offers the best path to lasting cure and fewer relapses.
Catalog record
| CREATOR | Godspower N. Okeke, Ugochukwu K. Oduwe, Giorgi Kenkebashvili, Shefa Tabassum, Alexandre F. Marques |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65552 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |